Valuation: Ligand Pharmaceuticals Incorporated

Market Cap 5.62B 4.81B 4.51B 4.12B 7.77B 535B 7.85B 53.19B 20.71B 270B 21.09B 20.63B 895B P/E 2026 *
53.8x
P/E 2027 * 33x
Enterprise Value 5.62B 4.81B 4.51B 4.12B 7.77B 535B 7.85B 53.19B 20.71B 270B 21.09B 20.63B 895B EV / Sales 2026 *
19.4x
EV / Sales 2027 * 14.8x
Free-Float
97.62%
Yield 2026 *
-
Yield 2027 * -
1 day+0.55%
1 week-2.04%
Current month-2.02%
1 month-6.26%
3 months+22.84%
6 months+47.20%
Current year+49.00%
1 week 278.28
Extreme 278.28
293.37
1 month 278.28
Extreme 278.28
317.49
Current year 175.89
Extreme 175.89
326.63
1 year 158.4
Extreme 158.4
326.63
3 years 49.24
Extreme 49.24
326.63
5 years 49.24
Extreme 49.24
326.63
10 years 49.24
Extreme 49.24
326.63
Manager TitleAgeSince
Chief Executive Officer 65 05/12/2022
Director of Finance/CFO 47 21/05/2015
Director of Finance/CFO 56 01/11/2022
Director TitleAgeSince
Chairman 76 01/03/2003
Director/Board Member 57 27/09/2006
Director/Board Member 65 01/03/2007
Date Insider Type Main position Quantity % Market Cap.
12/8/26 Fiscal year

Chief Financial Officer

94,923 0.4736%
12/8/26 Fiscal year

Director

19,414 0.0969%
3/8/26 Fiscal year

General Counsel

15,000 0.0748%
Change 5-day change 1-year change 3-year change Capi.($)
+0.55%-2.04%+77.42%+330.83% 5.62B
-1.06%+0.65%+77.42%+122.82% 1,100B
+0.04%+0.75%+53.10%+64.29% 658B
+0.48%+2.65%+28.06%+81.19% 470B
-0.68%+1.09%+43.29%+43.31% 372B
-0.39%+0.53%+26.18%+41.28% 304B
-1.17%+2.13%+3.66%+13.91% 264B
-0.36%+3.99%+53.31%+72.49% 239B
+0.27%+3.12%-12.01%-52.24% 213B
+1.38%+3.72%+30.33%+93.56% 184B
Average +0.04%+2.50%+38.08%+81.15% 380.85B
Weighted average by Cap. +0.07%+2.21%+45.82%+71.73%

Financials

2026 *2027 *
Net sales 290M 248M 233M 213M 401M 27.63B 405M 2.74B 1.07B 13.94B 1.09B 1.06B 46.17B 381M 326M 306M 279M 527M 36.28B 532M 3.6B 1.4B 18.3B 1.43B 1.4B 60.61B
Net income 112M 95.84M 89.81M 82.03M 155M 10.66B 156M 1.06B 412M 5.38B 420M 411M 17.82B 187M 160M 150M 137M 259M 17.82B 261M 1.77B 689M 8.99B 702M 686M 29.77B
Net Debt - -
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.
Employees
47
Date Price Change Volume
25/08/26 USD 281.72 +0.55% 197,406
24/08/26 USD 280.18 -2.13% 158,235
21/08/26 USD 286.29 -0.38% 152,536
20/08/26 USD 287.39 -1.14% 138,945
19/08/26 USD 290.71 +1.08% 231,199
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
281.72USD
Average target price
342.82USD
Spread / Average Target
+21.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LGND Stock